Economic Model of Uridine Triacetate Versus Supportive Care for the Treatment of Patients with Life-Threatening Early-Onset Severe Toxicity
Optimal treatment with uridine triacetate for all hospitalized patients in the USA expected to die from early-onset severe toxicity has the potential to improve inpatient survival at a minimal inpatient budget increase. The majority of the drug cost is offset by a reduction in the length of hospital stay and associated costs.
Authors
- Suzanne Ward (ORCID: https://orcid.org/0000-0002-5578-5058)
- Chantal M. Trepanier (ORCID: https://orcid.org/0000-0002-8726-8813)
- Alice Matthews Beers
- Setareh A. Williams (ORCID: https://orcid.org/0000-0002-6795-2677)
- Paige Reid
- Megan Bourque
- Angela Griffin (ORCID: https://orcid.org/0000-0003-1083-6189)
- Marinus Barnard
- Salvatore Miragliotta
Institutions
- Baptist Hospital of Miami (US)
- American Society For Testing and Materials (US)
- Baptist Health South Florida (US)
- EVERSANA (Canada) (CA)
- MedStar Health (US)
Publication Details
- Journal
- Clinical Drug Investigation
- Published
- 2025-02-22
- DOI
- https://doi.org/10.1007/s40261-025-01426-x
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00